Page last updated: 2024-11-06

edatrexate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

edatrexate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6917908
CHEMBL ID296373
CHEBI ID135757
SCHEMBL ID4676
SCHEMBL ID21248619
MeSH IDM0119855

Synonyms (36)

Synonym
80576-83-6
nsc-626715
cgp-30694
edatrexate
D03942
edatrexate (usan/inn)
n-(p-(1-((2,4-diamino-6-pteridinyl)methyl)propyl)benzoyl)-l-glutamic acid
edatrexato [inn-spanish]
l-glutamic acid, n-(4-(1-((2,4-diamino-6-pteridinyl)methyl)propyl)benzoyl)-
edatrexatum [inn-latin]
cgp 30694
edatrexate [usan:inn]
CHEBI:135757
gnf-pf-63 ,
CHEMBL296373 ,
TCMDC-137768 ,
(s)-2-{4-[1-(2,4-diamino-pteridin-6-ylmethyl)-propyl]-benzoylamino}-pentanedioic acid
bdbm50016460
edatrexato
edatrexatum
jt4x6z1hrr ,
nsc 626715
unii-jt4x6z1hrr
SCHEMBL4676
edatrexate [who-dd]
edatrexate [usan]
edatrexate [mart.]
edatrexate [mi]
edatrexate [inn]
cgp 30694;nsc 626715
SCHEMBL21248619
Q27281684
DTXSID901318475
CS-0007483
HY-13617
(2s)-2-(4-(1-(2,4-diaminopteridin-6-yl)butan-2-yl)benzamido)pentanedioic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"10-EDAM may provide an alternative antifolate therapy in the clinical management of inflammatory arthritis, and appears to be less toxic than MTX."( Comparative efficacy and toxicity of 10-ethyl-10-deazaaminopterin and methotrexate in a mycobacterial rat arthritis model.
Ramos-Remus, C; Russell, AS; Skeith, KJ, 1994
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacodynamic profiles of methotrexate (MTX) and 10-ethyl-10-deazaaminopterin (10-EdAM) were determined in three head and neck squamous cell carcinoma (HNSCC) cell lines."( Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma.
Braakhuis, BJ; Jansen, G; Kegel, A; Noordhuis, P; Peters, GJ, 1993
)
0.29

Compound-Compound Interactions

A Phase I dose escalation study of edatrexate in combination with a 3-h paclitaxel infusion was performed in patients with advanced breast cancer. The study was designed to determine the maximum tolerated dose (MTD) of ed Theatrexate and the toxicities associated with this combination.

ExcerptReferenceRelevance
"Motivated by the observation of preclinical synergy, a Phase I dose escalation study of edatrexate in combination with a 3-h paclitaxel infusion was performed in patients with advanced breast cancer to determine the maximum tolerated dose (MTD) of edatrexate and the toxicities associated with this combination and to report preliminary observations of efficacy with this novel combination."( Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
Baselga, J; D'Andrea, G; Fennelly, D; Gilewski, T; Hudis, C; Moynahan, ME; Norton, L; Raptis, G; Seidman, AD; Sklarin, N; Surbone, A; Templeton, MA; Theodoulou, M; Yao, TJ, 1999
)
0.3
" This Phase I study was designed to evaluate two schedules of administration of cisplatin in combination with escalating doses of edatrexate, in a population consisting mainly of patients with these two cancers."( Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Chronowski, G; Heelan, RT; Kris, MG; Laurie, SA; Pfister, DG; Pisters, KM; Sirotnak, FM; Tong, WP, 2001
)
0.31

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" These results suggest that this three-drug regimen may have synergistic antitumor effects, with a steep dose-response relationship, particularly with 10-EdAM."( Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer.
Dimery, IW; Fossella, FV; Glisson, BS; Hong, WK; Lee, JS; Libshitz, HI; Lippman, SM; Murphy, WK; Pang, AC; Shin, DM, 1991
)
0.28
" 10-Edam employed at this dosage and schedule was not effective as a treatment against advanced colorectal carcinoma."( Phase II trial of 10-Edam in patients with advanced colorectal carcinoma.
Israel, K; Kemeny, N; O'Hehir, M, 1990
)
0.28
" Despite the 2-fold attenuation of dosage required, antitumor activity of the combination (increased life span, 161%) was approximately twice that obtained with maximum tolerated doses of either agent alone and tumor-free, long-term survivors were obtained."( Intracavitary therapy of murine ovarian cancer with cis-diamminedichloroplatinum(II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection.
DeGraw, JI; Schmid, FA; Sirotnak, FM, 1989
)
0.28
" At the dosage and schedule used, 10-EDAM is an active agent in patients with NSCLC who are previously untreated with chemotherapy with a predicted response rate greater than or equal to 15% (P = ."( Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.
Burke, MT; Gralla, RJ; Heelan, RT; Kris, MG; Marks, LD; Shum, KY, 1988
)
0.27
" The dosage levels ranged from 5 to 120 mg/m2."( Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Fanucchi, MP; Farag, F; Gralla, RJ; Kinahan, JJ; Kris, MG; Marks, LD; O'Connell, JP; Wertheim, MS; Williams, L; Young, CW, 1988
)
0.27
" All two-drug combinations required attenuation to one-half the LD10 dosage for each."( Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
DeGraw, JI; Otter, GM; Schmid, FA; Sirotnak, FM,
)
0.13
" Carboplatin was given as an outpatient on day 1 at a dosage based on the formula: Dose (mg/m2) = (0."( Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck.
Benner, SE; Dimery, IW; Esparaz, B; Frenning, D; Guillory-Perez, C; Hong, WK; Huber, MH; Lippman, SM; Shirinian, M, 1994
)
0.29
" Combination therapy with EDX and vinca alkaloids required dosage attenuation but was still markedly more effective."( Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine.
Otter, GM; Sirotnak, FM, 1994
)
0.29
" Nine dosage levels ranging from 120 to 3750 mg/m2 were explored."( High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.
Bertino, JR; Densmore, CL; Fleisher, M; Grant, SC; Heelan, RT; Kris, MG; Krol, G; Miller, VA; Pfister, DG; Pisters, KM; Rigas, JR; Sirotnak, FM; Tong, W; Tyson, LB, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
glutamic acid derivativeAn amino acid derivative resulting from reaction of glutamic acid at the amino group or either of the carboxy groups, or from the replacement of any hydrogen by a heteroatom. The definition normally excludes peptides containing glutamic acid residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseHomo sapiens (human)IC50 (µMol)0.00350.00060.87267.3000AID57068; AID57109
Dihydrofolate reductaseMus musculus (house mouse)IC50 (µMol)0.01100.00200.99697.0000AID57295
Dihydrofolate reductaseMus musculus (house mouse)Ki0.33000.00000.21713.9000AID57443; AID57451; AID57455
Dihydrofolate reductaseLacticaseibacillus caseiIC50 (µMol)0.01780.00130.26964.9000AID56786; AID57932; AID57933; AID57934; AID57935
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseMus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (101)

Assay IDTitleYearJournalArticle
AID99537Inhibitory activity against the growth of Streptococcus faecium (ATCC 8043) was determined (glutamate residue 4)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID56786Compound was tested for the inhibition of dihydrofolate reductase in Bovine liver1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID99543Inhibitory activity against thymidylate synthase in Lactobacillus casei was determined (glutamate residue 3)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID135705Compound was evaluated for the activity against LC-6 Non-Small cell lung carcinoma in mice by tumor weight assay at 10 (mg/kg) dose in experiment-11994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID231772Ratio of compound activity to that of MTX activity.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Folate analogues. 34. Synthesis and antitumor activity of non-polyglutamylatable inhibitors of dihydrofolate reductase.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID57932Inhibitory activity against dihydrofolate reductase in Lactobacillus casei was determined (glutamate residue 2)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID57276Tested in vitro for relative activity against CCRF-CEM human Leukemic lymphoblast by using DHFR as primary target1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
AID135866Compound was evaluated for the life span assay against P388 Leukemia in mice (Controls died in an average of 9.8 days) at 0.2 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID150668Inhibitory concentration of compound was tested against P388 tumor growth cell line1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID95870Inhibitory concentration of compound was tested against KB tumor growth cell line1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID135847Compound was evaluated for the activity against LC-6 Non-Small cell lung carcinoma in mice by tumor weight assay at 20 (mg/kg) dose experiment-11994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID129837Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 23 at intraperitoneal dose of 18 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID135870Compound was evaluated for the life span assay against P388 Leukemia in mice (Controls died in an average of 9.8 days) at 12.5 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID50576Inhibitory concentration of compound was tested against Colon 38 tumor growth cell line1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID135697Compound was evaluated for the activity against Colon 26 Mouse colorectal carcinoma in mice by tumor weight assay at 10 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID135867Compound was evaluated for the life span assay against P388 Leukemia in mice (Controls died in an average of 9.8 days) at 0.39 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID150669Inhibitory concentration of compound was tested against P388:Methotrexate resistant cells tumor growth cell line1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID135176Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 44 at intraperitoneal dose of 18 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID135157Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 37 at intraperitoneal dose of 12 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID57443Binding affinity towards Dihydrofolate reductase derived from L1210 cells using [3H]- MTX as the radioligand1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and antifolate properties of 9-alkyl-10-deazaminopterins.
AID99535Inhibitory activity against the growth of Streptococcus faecium (ATCC 8043) was determined (glutamate residue 2)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID99402Inhibitory activity against the growth of Lactobacillus casei (ATCC 7469) was determined (glutamate residue 3)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID57455Inhibition of Dihydrofolate reductase (DHFR) enzyme derived from L1210 cells expressed as Ki (pM)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID135161Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 37 at intraperitoneal dose of 18 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID135850Compound was evaluated for the activity against LC-6 Non-Small cell lung carcinoma in mice by tumor weight assay at 40 (mg/kg) dose experiment-21994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID57068Compound was tested for its inhibitory activity on Recombinant Human Dihydrofolate Reductase.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Folate analogues. 34. Synthesis and antitumor activity of non-polyglutamylatable inhibitors of dihydrofolate reductase.
AID135848Compound was evaluated for the activity against LC-6 Non-Small cell lung carcinoma in mice by tumor weight assay at 20 (mg/kg) dose experiment-21994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID134996Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 23 at intraperitoneal dose of 12 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID135704Compound was evaluated for the activity against LC-6 Non-Small cell lung carcinoma in mice by tumor weight assay at 10 (mg/kg) dose experiment-21994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID99542Inhibitory activity against thymidylate synthase in Lactobacillus casei was determined (glutamate residue 2)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID99403Inhibitory activity against the growth of Lactobacillus casei (ATCC 7469) was determined (glutamate residue 4)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID99540Inhibitory activity against the growth of Streptococcus faecium (ATCC 8043) was determined (glutamate residue 6); No data1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID57934Inhibitory activity against dihydrofolate reductase in Lactobacillus casei was determined (glutamate residue 4)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID135869Compound was evaluated for the life span assay against P388 Leukemia in mice (Controls died in an average of 9.8 days) at 1.56 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID129834Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 23 at intraperitoneal dose of 12 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID57451Concentration inhibiting dihydrofolate reductase derived from L1210 cells1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and antifolate properties of 9-alkyl-10-deazaminopterins.
AID129991Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 37 at intraperitoneal of dose 12 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID135871Compound was evaluated for the life span assay against P388 Leukemia in mice (Controls died in an average of 9.8 days) at 3.13 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID99406Inhibitory activity against the growth of Lactobacillus casei (ATCC 7469) was determined (glutamate residue 6); No data1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID135873Compound was evaluated for the life span assay against P388 Leukemia in mice (Controls died in an average of 9.8 days) at 6.25 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID129994Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 37 at intraperitoneal of dose 18 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID135171Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 44 at intraperitoneal dose of 12 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID44022Growth inhibition of CCRF-CEM human leukemic lymphoblasts2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Analogues of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine (PT523) with modifications in the side chain, p-aminobenzoyl moiety, or 9,10-bridge: synthesis and in vitro antitumor activity.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID57935Inhibitory activity against dihydrofolate reductase in Lactobacillus casei was determined (glutamate residue 5)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID52667Inhibitory concentration of compound was tested against Colon 26 Mouse Colorectal Carcinoma on 4 hour exposure1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID52668Inhibitory concentration of compound was tested against Colon 26 tumor growth cell line1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID98160Concentration inhibiting L1210 cell growth in culture1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and antifolate properties of 9-alkyl-10-deazaminopterins.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID99401Inhibitory activity against the growth of Lactobacillus casei (ATCC 7469) was determined (glutamate residue 2)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID132684Inhibition of growth in L1210 murine leukemia cells in culture expressed as IC50 (nM)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin.
AID130003Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 44 at intraperitoneal of dose 12 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID99547Inhibitory activity against thymidylate synthase in Lactobacillus casei was determined (glutamate residue 6); ND=No data1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID57295Compound was tested for the inhibition of dihydrofolate reductase in P388 cells1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID99541Inhibitory activity against thymidylate synthase in Lactobacillus casei was determined (glutamate residue 1)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID99544Inhibitory activity against thymidylate synthase in Lactobacillus casei was determined (glutamate residue 4)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID99534Inhibitory activity against the growth of Streptococcus faecium (ATCC 8043) was determined (glutamate residue 1)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID134218Transport influx which is determined by competitive binding for the transport protein; expressed as Ki (uM)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID135011Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 30 at intraperitoneal dose of 12 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID99538Inhibitory activity against the growth of Streptococcus faecium (ATCC 8043) was determined (glutamate residue 5)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID135000Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 23 at intraperitoneal dose of 18 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID129849Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 30 at intraperitoneal of dose 18 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID135699Compound was evaluated for the activity against Colon 26 Mouse colorectal carcinoma in mice by tumor weight assay at 20 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID99400Inhibitory activity against the growth of Lactobacillus casei (ATCC 7469) was determined (glutamate residue 1)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID57109Tested in vitro for inhibitory concentration against CCRF-CEM human Leukemic lymphoblast by using DHFR as primary target1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
AID99404Inhibitory activity against the growth of Lactobacillus casei (ATCC 7469) was determined (glutamate residue 5)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID99545Inhibitory activity against thymidylate synthase in Lactobacillus casei was determined (glutamate residue 5)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID99536Inhibitory activity against the growth of Streptococcus faecium (ATCC 8043) was determined (glutamate residue 3)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID134993Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on 30 at intraperitoneal dose of 18 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID135868Compound was evaluated for the life span assay against P388 Leukemia in mice (Controls died in an average of 9.8 days) at 0.78 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID129846Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 30 at intraperitoneal of dose 12 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID130006Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 44 at intraperitoneal of dose 18 mg/kg1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.
AID57937Inhibitory activity against dihydrofolate reductase in Lactobacillus casei was determined (glutamate residue 6); No data1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID57933Inhibitory activity against dihydrofolate reductase in Lactobacillus casei was determined (glutamate residue 3)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (113)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (11.50)18.7374
1990's89 (78.76)18.2507
2000's9 (7.96)29.6817
2010's2 (1.77)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials34 (29.06%)5.53%
Reviews17 (14.53%)6.00%
Case Studies2 (1.71%)4.05%
Observational0 (0.00%)0.25%
Other64 (54.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]